3053716-46-1
Chemical Structure
ZLC491
- CAS No.: 3053716-46-1
- Formula:C48H51FN10O5
- Molecular Weight:866.98
InChIKey: NWDSPIBOUKKLKG-AIBFIVBUSA-N
SMILES: O=C(N([C@@H]1CC[C@H](CC1)NC2=CC=C(C=N2)C#N)C3=CC=C(C=C3)N4CCN(CC4)C5CCN(CC5)C6=CC7=C(C=C6F)C(N(C7=O)C8CCC(NC8=O)=O)=O)NCC9=CC=CC=C9
Biological Activity: ZLC491 is an orally active PROTAC degrader that selectively targets CDK12/CDK13 and exhibits certain oral bioavailability. ZLC491 induces cereblon- and proteasome-dependent selective degradation of CDK12 and CDK13. ZLC491 inhibits the transcription and expression of long genes, and mainly acts on a subset of DNA damage response genes. ZLC491 inhibits the proliferation of various triple-negative breast cancer cells. ZLC491 can be used in research related to triple-negative breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ZLC491 | 98.51% | ZLC491 is an orally active PROTAC degrader that selectively targets CDK12/CDK13 and exhibits certain oral bioavailability. ZLC491 induces cereblon- and proteasome-dependent selective degradation of CDK12 and CDK13. ZLC491 inhibits the transcription and expression of long genes, and mainly acts on a subset of DNA damage response genes. ZLC491 inhibits the proliferation of various triple-negative breast cancer cells. ZLC491 can be used in research related to triple-negative breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
